Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas, Amir Nikooienejad, Ross Bray, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 106, Iss. 2, pp. 388-396
Open Access | Times Cited: 207

Showing 26-50 of 207 citing articles:

Structural determinants of dual incretin receptor agonism by tirzepatide
Bingfa Sun, Francis S. Willard, Dan Feng, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 13
Open Access | Times Cited: 68
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 53
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Ricardo J. Samms, Guo‐Fang Zhang, Wentao He, et al.
Molecular Metabolism (2022) Vol. 64, pp. 101550-101550
Open Access | Times Cited: 48
Tirzepatide: A Systematic Update
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14631-14631
Open Access | Times Cited: 48
Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta‐analysis
Paschalis Karakasis, Dimitrios Patoulias, Nikolaos Fragakis, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 1090-1104
Closed Access | Times Cited: 28
Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
Clare J. Lee, Huzhang Mao, Vivian T. Thieu, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 5
Open Access | Times Cited: 27
Tirzepatida: Un Avance Revolucionario en el Tratamiento de la Diabetes Mellitus Tipo 2 y la Obesidad
Mariana Chávez
Revista Veritas de Difusão Cientifica. (2023) Vol. 4, Iss. 1, pp. 96-110
Open Access | Times Cited: 26
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Qingyue Zeng, Jiao Xu, Xingyu Mu, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 25
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 14
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Muhammad Abdul-Ghani, Pietro Maffei, Ralph A. DeFronzo
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 9, pp. 674-680
Closed Access | Times Cited: 14
Insulin–Heart Axis: Bridging Physiology to Insulin Resistance
Alfredo Caturano, Raffaele Galiero, Erica Vetrano, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8369-8369
Open Access | Times Cited: 12
Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis
Yi Pan, Tong Bu, Xia Deng, et al.
Endocrine (2024) Vol. 84, Iss. 1, pp. 1-15
Closed Access | Times Cited: 11
The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
Thomas Leth Jensen, Andreas Brønden, Kristian Karstoft, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 373-382
Open Access | Times Cited: 11
Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity
Muhammad Bilal Sardar, Zain Ali Nadeem, Muhammad Zafar Majeed Babar
Current Problems in Cardiology (2024) Vol. 49, Iss. 5, pp. 102489-102489
Closed Access | Times Cited: 11
Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review
L Konings, Lorena Miguelañez‐Matute, Anna M P Boeren, et al.
European Journal of Clinical Investigation (2025)
Open Access | Times Cited: 1
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
Takashi Kadowaki, Arihiro Kiyosue, Tomotaka Shingaki, et al.
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 1
Recent advances in understanding the role of glucagon-like peptide 1
Josh Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi
F1000Research (2020) Vol. 9, pp. 239-239
Open Access | Times Cited: 52
Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
João Victor da Silva Guerra, Marieli M. G. Dias, Anna Julyana Viana Chianca Brilhante, et al.
Nutrients (2021) Vol. 13, Iss. 8, pp. 2830-2830
Open Access | Times Cited: 48
Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics
Anita Kabahizi, Briana Wallace, Linh Lieu, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 600-624
Open Access | Times Cited: 43
Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
Deep Dutta, Vineet Surana, Rajiv Singla, et al.
Indian Journal of Endocrinology and Metabolism (2021) Vol. 25, Iss. 6, pp. 475-489
Open Access | Times Cited: 43
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
Ali A. Rizvi, Manfredi Rizzo
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 1023-1030
Open Access | Times Cited: 37
Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?
Laura Valenzuela‐Vallejo, Valentina Guatibonza-García, Christos S. Mantzoros
Metabolism (2022) Vol. 136, pp. 155248-155248
Closed Access | Times Cited: 32
Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics
Liliane El Eid, Christopher A. Reynolds, Alejandra Tomás, et al.
Pharmacological Research (2022) Vol. 184, pp. 106411-106411
Open Access | Times Cited: 29
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Gianfranco Di Giuseppe, Gea Ciccarelli, Laura Soldovieri, et al.
Trends in Endocrinology and Metabolism (2023) Vol. 34, Iss. 4, pp. 216-230
Open Access | Times Cited: 19

Scroll to top